Journal article

Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research

James M Foran, Steven Z Pavletic, Brent R Logan, Manza A Agovi-Johnson, Waleska S Perez, Brian J Bolwell, Martin Bornhaeuser, Christopher N Bredeson, Mitchell S Cairo, Bruce M Camitta, Edward A Copelan, Jason Dehn, Robert P Gale, Biju George, Vikas Gupta, Gregory A Hale, Hillard M Lazarus, Mark R Litzow, Dipnarine Maharaj, David I Marks Show all

Biology of Blood and Marrow Transplantation | ELSEVIER SCIENCE INC | Published : 2013


Awarded by Public Health Service Grant/Cooperative Agreement, National Cancer Institute

Awarded by National Cancer Institute

Awarded by Health Resources and Services Administration

Awarded by Office of Naval Research

Funding Acknowledgements

The Center for International Blood and Marrow Transplant Research is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute, the National Heart, Lung and Blood Institute, and the National Institute of Allergy and Infectious Diseases; Grant/Cooperative Agreement 5U01HL069294 from the National Cancer Institute and the National Heart, Lung and Blood Institute; Contract HHSH234200637015C with the Health Resources and Services Administration; Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; and grants from Allos, Amgen, Angioblast, anonymous donation to the Medical College of Wisconsin, Ariad, Be the Match Foundation, Blue Cross and Blue Shield Association, Buchanan Family Foundation, CaridianBCT, Celgene, CellGenix, Children's Leukemia Research Association, Fresenius-Biotech North America, Gamida Cell Teva Joint Venture, Genentech, Genzyme, GlaxoSmithKline, HistoGenetics, Kiadis Pharma, Leukemia and Lymphoma Society, Medical College of Wisconsin, Merck & Co, Millennium: Takeda Oncology, Milliman USA, Miltenyi Biotec, National Marrow Donor Program, Optum Healthcare Solutions, Osiris Therapeutics, Otsuka America Pharmaceutical, RemedyMD, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals, Soligenix, StemCyte, Stemsoft Software, Swedish Orphan Biovitrum, Tarix Pharmaceuticals, Teva Neuroscience, Therakos, and Wellpoint. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government.